GLP Pharma Ltd

	Page
Abridged Balance Sheet	1—2
Notes to the Abridged Financial Statements	3—4

Registered number: 12468870

		2026		2025
	Notes	£	£	£	£
FIXED ASSETS
Tangible Assets	4		399,949		314,047
Investments	5		3,829,330		3,829,330

			4,229,279		4,143,377
CURRENT ASSETS
Debtors		4,217		4,002
Cash at bank and in hand		6,573		12,849

		10,790		16,851
Creditors: Amounts Falling Due Within One Year		(1,180,562 )		(950,193 )

NET CURRENT ASSETS (LIABILITIES)			(1,169,772 )		(933,342 )

TOTAL ASSETS LESS CURRENT LIABILITIES			3,059,507		3,210,035

Creditors: Amounts Falling Due After More Than One Year			(2,226,801 )		(2,373,456 )

NET ASSETS			832,706		836,579

CAPITAL AND RESERVES
Called up share capital	6		2		2
Capital redemption reserve			1		1
Profit and Loss Account			832,703		836,576

SHAREHOLDERS' FUNDS			832,706		836,579

Page 1

Page 2

GLP Pharma Ltd

Abridged Balance Sheet (continued)

As At 28 February 2026

For the year ending 28 February 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

All of the company's members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet for the year end 28 February 2026 in accordance with section 444(2A) of the Companies Act 2006.

On behalf of the board

Mr M W Harvey

Director

3 September 2026

The notes on pages 3 to 4 form part of these financial statements.

1. General Information

GLP Pharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12468870 . The registered office is 61 Rodney Street, Liverpool, Merseyside, L1 9ER.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold

2% on cost

3. Average Number of Employees

Average number of employees, including directors, during the year was: 2 (2025: 2)

4. Tangible Assets

	Total
	£
Cost
As at 1 March 2025	320,456
Additions	93,493

As at 28 February 2026	413,949

Depreciation
As at 1 March 2025	6,409
Provided during the period	7,591

As at 28 February 2026	14,000

Net Book Value
As at 28 February 2026	399,949

As at 1 March 2025	314,047

5. Investments

	Total
	£
Cost
As at 1 March 2025	3,829,330

As at 28 February 2026	3,829,330

Provision
As at 1 March 2025	-

As at 28 February 2026	-

...CONTINUED

Page 3

Page 4

GLP Pharma Ltd

Notes to the Abridged Financial Statements (continued)

For The Year Ended 28 February 2026

Net Book Value
As at 28 February 2026	3,829,330

As at 1 March 2025	3,829,330

6. Share Capital

	2026	2025
	£	£
Allotted, Called up and fully paid	2	2